MDR 5.13% 41.0¢ medadvisor limited

Ann: MDR March 2018 Quarterly Report & Appendix 4C, page-3

  1. 334 Posts.
    lightbulb Created with Sketch. 2
    From my understanding they are still not monetising tap-to-refill, once they turn the tap on here we should see some great revenue growth. Still a hold for me, lots of potential share price catalysts in the near to medium term.
 
watchlist Created with Sketch. Add MDR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.